(Q36528120)

14 August 2017

A cell-penetrating peptidic GRP78 ligand for tumor cell-specific prodrug therapy (English)

1 reference

14 August 2017

Yoshiyuki Yoneda

1

1 reference

14 August 2017

Sebastian C J Steiniger

2

1 reference

14 August 2017

Katerina Capková

3

1 reference

14 August 2017

Jenny M Mee

4

1 reference

14 August 2017

Ying Liu

5

1 reference

14 August 2017

Gunnar F Kaufmann

6

1 reference

14 August 2017

Kim D Janda

7

1 reference

14 August 2017

language of work or name

English

0 references

publication date

19 January 2008

1 reference

Bioorganic & Medicinal Chemistry Letters

14 August 2017

1 reference

14 August 2017

18

1 reference

14 August 2017

5

1 reference

14 August 2017

1632-1636

1 reference

Mechanistic studies of a peptidic GRP78 ligand for cancer cell-specific drug delivery

14 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2288489

Association of elevated GRP78 expression with increased lymph node metastasis and poor prognosis in patients with gastric cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2288489

Synthesis and biological in vitro evaluation of novel PEG-psoralen conjugates

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2288489

Targeting heat shock proteins on cancer cells: selection, characterization, and cell-penetrating properties of a peptidic GRP78 ligand

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2288489

Glucose regulated proteins in cancer progression, drug resistance and immunotherapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2288489

Dipeptide-based highly potent doxorubicin antibody conjugates

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2288489

Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2288489

Molecular regulation of human cathepsin B: implication in pathologies

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2288489

Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2288489

Paclitaxel derivatives for targeted therapy of cancer: toward the development of smart taxanes.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2288489

Self-immolative anthracycline prodrugs for suicide gene therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2288489

Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2288489

Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2288489

Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2288489

Protease-mediated fragmentation of p-amidobenzyl ethers: a new strategy for the activation of anticancer prodrugs

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2288489

Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin

21 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18243696

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18243696

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.BMCL.2008.01.060

1 reference

14 August 2017

1 reference

14 August 2017

PubMed publication ID

18243696

1 reference